, Volume 5, Issue 2, pp 57-58
Date: 15 Apr 2011

Optimizing Amphotericin B Therapy for Cryptococcal Meningitis

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Hamill RJ, Sobel JD, El-Sadr W, Johnson PC, Graybill JR, Javaly K, Barker DE, and AmBisome Cryptococcal Meningitis Study Group: Comparison of 2 doses of liposomal amphotericin b and conventional amphotericin b deoxycholate for treatment of AIDS-associated acute cryptococcal meningitis: a randomized, double-blind clinical trial of efficacy and safety.Clin Infect Dis 2010, 51:225–232.

Rating: •Of importance.

Introduction: Although the introduction of highly active antiretroviral therapy (HAART) has decreased the incidence of cryptococcal meningitis associated with AIDS in many countries, it is still common, especially among populations with limited access to medical care [1]. Using a regimen of amphotericin B deoxycholate (0.7–1.0 mg/kg per day), with or without flucytosine, mortality rates associated with the treatment of cryptococcal meningitis have been reported to be 5% to 11% and cerebrospinal fluid (CSF) sterilization rates were reported to be 60% to 75% [2, 3].

Lipid-based formulatio